Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 530 (1 May 2008) | doi:10.1038/nbt0508-530
Research highlights
Abstract
siRNA activates TLR3 Several small interfering RNA (siRNA)-based drugs are already showing promise in clinical trials, including one for macular degeneration that inhibits angiogenesis purportedly by targeting vascular endothelial growth factor (VEGF). But now, Kleinman and colleagues cast doubt on the exquisite target specificity often claimed for the approach by showing that siRNA suppression of angiogenesis can be sequence independent.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
